Because of the small sample size of our cohorts, it did not yield many statistically significant results, but from the available data, a pronounced trend showed that female patients receiving immunotherapy in both first‐ and second‐line therapies tended to achieve potentially longer survival and better response.
← all excerpts
Women patients with small-cell lung cancer using immunotherapy in a real-world cohort achieved long-term survival.
1
—
—